uniQure (NASDAQ:QURE) Shares Gap Up – Here’s Why

uniQure N.V. (NASDAQ:QURE)’s share price gapped up before the market opened on Friday . The stock had previously closed at $22.69, but opened at $23.95. uniQure shares last traded at $25.15, with a volume of 914,442 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on QURE shares. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Royal Bank Of Canada cut their price objective on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. HC Wainwright lowered their target price on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Finally, Wells Fargo & Company reduced their price objective on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $60.82.

uniQure Stock Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The company has a market capitalization of $1.55 billion, a PE ratio of -5.65 and a beta of 0.68. The stock has a 50-day simple moving average of $24.22 and a 200 day simple moving average of $27.94.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. Equities analysts anticipate that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 102,247 shares of company stock worth $2,839,298 over the last quarter. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently modified their holdings of the company. Swiss National Bank purchased a new stake in uniQure in the 2nd quarter worth approximately $1,080,000. Sanders Morris Harris LLC purchased a new stake in shares of uniQure in the third quarter valued at $5,081,000. Aberdeen Group plc increased its stake in uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after purchasing an additional 535,163 shares during the last quarter. Jennison Associates LLC purchased a new position in uniQure during the second quarter worth about $1,952,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in uniQure in the 2nd quarter worth about $872,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.